Cytokinetics reports positive 48-week FOREST-HCM data on aficamten at ACC

CYTOKINETICS INC

46 patients completed 48 weeks; 75% on 15mg or 20mg dose of aficamten.
Mean resting LVOT-G reduced by 39.6 mmHg (p<0.0001) and Valsalva LVOT-G by 53.2 mmHg.
82.2% improved by ≥1 NYHA class; no worsening class observed.
NT-proBNP decreased 63% (p<0.001); SRT-eligibility reduced 94%.
No treatment-related SAEs; modest LVEF reduction (-5.1%) with three dose adjustments.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.